相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender
I. Y. K. Iskandar et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results
M. Augustin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate-to-severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI-PSO study
M. -A. Richard et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review
E. Fowler et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Psoriasis: Which therapy for which patient Focus on special populations and chronic infections
Shivani B. Kaushik et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderateto-severe psoriasis through 2 years of treatment: Results from the CLEAR study
Diamant Thaci et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks
Esther von Stebut et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies
Chen-Yu Wu et al.
PLOS ONE (2019)
Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review
Igor Snast et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
Simone Ribero et al.
CASE REPORTS IN DERMATOLOGY (2019)
Latent tuberculosis infection: Opportunities and challenges
Cynthia B. E. Chee et al.
RESPIROLOGY (2018)
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2018)
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
Peter Nash et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)
Vibeke Strand et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2017)
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Jerry Bagel et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
Fabrizio Cantini et al.
MEDIATORS OF INFLAMMATION (2017)
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
Iain B. McInnes et al.
RHEUMATOLOGY (2017)
Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials
Zheng Zhang et al.
BMJ OPEN (2017)
Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab
Chuan-Yu Hsiao et al.
PLOS ONE (2017)
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial
M. Sticherling et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
Michael Kammueller et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2017)
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C. M. van de Kerkhof et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Rein M. G. J. Houben et al.
PLOS MEDICINE (2016)
Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis A Phase III Randomized Trial (MEASURE 1)
Atul A. Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Serial QuantiFERON-TB Gold In-Tube testing for psoriatic patients receiving antitumor necrosis factor-alpha therapy
Chun-Yu Cheng et al.
DERMATOLOGICA SINICA (2015)
Infection risk associated with anti-TNF-α agents: a review
Giuseppe Murdaca et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Ulrich Mrowietz et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Diagnosis and Management of Latent Tuberculosis Infection
Laura Munoz et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2015)
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
C. Paul et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)
Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area
Hye Won Kim et al.
CLINICAL RHEUMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Canadian Rheumatology Association Recommendations for the Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety
Claire Bombardier et al.
JOURNAL OF RHEUMATOLOGY (2012)
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
I. Solovic et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
IL-23 and IL-17 in tuberculosis
Shabaana A. Khader et al.
CYTOKINE (2008)
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment
LP Ormerod et al.
THORAX (2005)
IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-γ responses if IL-12p70 is available
SA Khader et al.
JOURNAL OF IMMUNOLOGY (2005)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
